I showed this abstract to a well regarded MFM specialist yesterday and he was lukewarm on it. He didn't have high regard for the researchers and said the journal it was published in is somewhat obscure. Even with this new info he would not recommend Lovenox for me, which is pretty much in line with what every other doctor I've seen has said.

I used the lovenox for my 2nd pregnancy which ended in miscarriage, didn't use it for my 3rd and delivered at 36 wks. BUT the placental report came back that the placenta was small for age and had infarcts. The same report as with my 1st pregnancy. So were I to get pregnant again, this time I think I'll ask for both the lovenox & LDA.

I met with 2 different MFM practices and they were totally mixed on it. One wouldn't do it because there was not enough significant research to support it and they wouldn't do anything without research, the other thought we should try it, but would have been okay if I'd nixed it too. (In addition to HELLP, we had severe IUGR at 23 weeks, like 4 weeks behind, and at my last ultrasound they could see reverse bloodflow.) I ultimately decided that it was a risk I wanted to take, although I'll probably be off of it totally by around 30 weeks if everything is going well, so far we've had no issues with the lovenox and the baby's actually measuring ahead this time. We'll never know if it was even the lovenox (and LDA) that helped or just being a subsequent pregnant helped or just a new placenta, but I didn't want to regret not doing it. If your current MFM doesn't agree to it and you decide you want to do it, it probably wouldn't be that difficult to find an MFM who would okay it.

[b]I just noticed this and wondered if anyone had thoughts on it?[/b] I don't have any thrombophilias, but not sure about the pathological placenta, have to double check my records for that one. My doc has said no to the lovenox (in a future pregnancy) since I don't have a diagnosed thrombophilia, but this makes me wonder if I should push it.

http://www.ncbi.nlm.nih.gov/pubmed/21192252

[b]Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia.[/b]Low molecular weight heparin (LMWH) treatment has been recommended for pregnant women with previous adverse pregnancy and who were diagnosed as having a thrombophilia. We now examined the effect of LMWH on pregnant women without thrombophilias who had severe pregnancy complications and placental vasculopathy in an earlier pregnancy......[skip to the conclusion]:Treatment with LMWH may reduce the rate of the recurrence of severe pregnancy complications and significant placental vasculopathy in women [i]without thrombophilias[/i].